Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

NCT04512066 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04512066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04512066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
September 8, 2020
Completion date
June 21, 2022
Enrollment
287 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia, schizoaffective disorder